Tandem Diabetes Care Inc [TNDM] stock is trading at $15.21, up 5.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TNDM shares have gain 0.73% over the last week, with a monthly amount glided 1.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on September 08, 2025, and set its price target to $22. On August 12, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $10.35 on the stock. Piper Sandler downgraded its rating to a Neutral but stick to its price target of $14 on August 07, 2025. Citigroup downgraded its rating to a Sell but $14 remained the price target by the analyst firm on July 09, 2025. Truist started tracking with a Hold rating for this stock on June 16, 2025, and assigned it a price target of $24. In a note dated April 10, 2025, Mizuho initiated a Neutral rating and provided a target price of $20 on this stock.
Tandem Diabetes Care Inc [TNDM] stock has fluctuated between $9.98 and $38.28 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Tandem Diabetes Care Inc [NASDAQ: TNDM] shares were valued at $15.21 at the most recent close of the market. An investor can expect a potential return of 24.92% based on the average TNDM price forecast.
Analyzing the TNDM fundamentals
Tandem Diabetes Care Inc [NASDAQ:TNDM] reported sales of 1.00B for the trailing twelve months, which represents a growth of 8.46%. Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.18%, and Net Profit Margin reading is -0.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -1.04 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.45 points at the first support level, and at 13.69 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.66, and for the 2nd resistance point, it is at 16.12.
Ratios To Look Out For
For context, Tandem Diabetes Care Inc’s Current Ratio is 2.44. As well, the Quick Ratio is 1.88, while the Cash Ratio is 0.25. Considering the valuation of this stock, the price to sales ratio is 1.03, the price to book ratio is 7.71.
Transactions by insiders
Recent insider trading involved Sheridan John F, PRESIDENT & CEO, that happened on Aug 11 ’25 when 10000.0 shares were purchased. EVP & CHIEF FINANCIAL OFFICER, Vosseller Leigh completed a deal on Aug 08 ’25 to buy 13720.0 shares. Meanwhile, EVP & Chief Operating Officer Kyrillos Jean-Claude bought 10538.0 shares on Mar 07 ’25.
